… [VIDEO & SLIDES] Alex Chehrazi –Raffle, MD, City of Hope – 2024 MOASC Annual Oncology Summit & Research Symposium…
Browsing: ASCO 2023
By. Allen WilbanksDate. 11/23/2023Lot Aronson, MD, a medical doctor and researcher from the Department of Gynecologic Oncology in the Netherlands…
Dr. Jack West, MD, an associate professor in medical oncology focused on thoracic oncology at the City of Hope Comprehensive…
In ASCO 2023, the highly anticipated results of the Adora study were unveiled, providing valuable insights into the efficacy and impact…
Manojkumar Bupathi, MD, from the Rocky Mountain Cancer Centers, conducted a study to evaluate the effectiveness of sacituzumab govitecan (SG)…
Anthony Stein, MD, from the City of Hope, has conducted a first-in-human study to evaluate the safety and efficacy of…
Majid Jaberi-Douraki, PhD from Kansas State University, and Shahzad Raza, MD from the Cleveland Clinic, conducted a study to evaluate…
Manojkumar Bupathi, MD, MS, from Rocky Mountain Cancer Centers, conducted a safety analysis on cohort 1 of the TROPHY-U-01 phase…
Ismael Rodriguez Rivera, MD, Medical Oncologist and Clinical Investigator from NEXT Oncology, has conducted a groundbreaking study on a novel…
Erika Hamilton, MD, a preeminent expert from the Sarah Cannon Research Institute, has recently conducted a study evaluating the efficacy…
Nadia Harbeck, MD, PhD, from the University of Münster, recently conducted a primary outcome analysis of the multicenter randomized PreCycle…
Roy Herbst, MD, PhD, from the Yale Cancer Center and Yale School of Medicine, presented a groundbreaking abstract at the…
Caicun Zhou, MD, PhD – Tongji University Shanghai Pulmonary Hospital Sunvozertinib established itself as the leading targeted therapy for NSCLC…
Laure-Anne Teuwen, MD, PhD from Antwerp University Hospital, and Joanna Young, DO, FACP from Blue Ridge Cancer Care examined the…
Patrizia Giannatempo, MD, from the Fondazione IRCCS Istituto Nazionale dei Tumori, has conducted extensive research on the impact of histology…
Prof. Arun Azad, MBBS, PhD from the Peter MacCallum Cancer Centre, has recently conducted a Phase 3 clinical trial called…
Monique Hartley-Brown, MD, MMSc, from Dana-Farber Cancer Institute, conducted a significant clinical study called “SUCCESSOR-2” that focused on the treatment…
Karan Dixit, MD, from Northwestern Medicine, delivered a compelling presentation during the Plenary Session at the recent conference on glioma…
Rona Yaeger, MD, an eminent oncologist from Memorial Sloan Kettering Cancer Center, is currently involved in a significant clinical trial…
Ticiana Leal, MD, from the Winship Cancer Institute of Emory University, has conducted a randomized, phase 3 study called LUNAR,…
Petros Grivas, MD, PhD, an expert in urothelial carcinoma (UC) research at the University of Washington, has made significant contributions…
Sara Tolaney, MD, a renowned researcher from the Dana-Farber Cancer Institute, has recently conducted a groundbreaking study that has been…
Jason Luke, MD, FACP, a renowned medical professional affiliated with the University of Pittsburgh Medical Center (UPMC), recently conducted a…
Swetha Kambhampati, MD from the City of Hope talks about the ASCO 2023 abstract about Mantle Cell Lymphoma Real-World Outcomes of…
The phase 3 FRESCO-2 study evaluated the efficacy and safety of fruquintinib, a novel targeted therapy, in patients with advanced…
Ferdinandos Skoulidis, MD, PhD, from the MD Anderson Cancer Center, presented the results of biomarker subgroup analyses from the phase…
J. Randolph Hecht, MD from UCLA Health is conducting a phase 3 clinical trial called STELLAR-303 to evaluate the efficacy…
Corina Dutcus, MD from Eisai Inc provided a summary of the findings from a clinical trial evaluating the combination of…
Adam Brufsky, MD, PhD from the University of Pittsburgh discussed the higher risk of recurrence in certain breast cancer patients…
Dr. Monica Niger, from Fondazione IRCCS Istituto Nazionale Tumori, provided a summary of the NALIRIFOX vs FOLFIRINOX vs gemcitabine plus…
Dr. Katherine Peters from Duke University Medical Center discussed the current treatments and their limitations for low-grade glioma patients with…
“Correction: The mPFS is not 34 months but 34%.” Carolina Schinke, MD from the UASM Health provided insights into the…
Dr. Timothy Cloughesy, a prominent physician from UCLA Health, conducted the INDIGO clinical trial to evaluate the efficacy of Vorasidenib,…
Dr. Brian Hill, MD, PhD, from the Cleveland Clinic presented a study conducted through the Alliance and US cooperative groups,…
In this study, the researchers evaluated the use of standard of care (SOC) ciltacabtagene autoleucel in a patient population and…
Dr. David Peereboom from Cleveland Clinic conducted a phase one clinical trial called CRUX to investigate the efficacy and safety…
Dr. Jessica Geiger from Cleveland Clinic presented an abstract at ASCO 2023 highlighting the potential of Enfortumab vedotin as a…
Dr. Atulya Khosla discussed the “Saved by the Scan” public service advertising program initiated by the American Lung Association (ALA)…
Dr. Suneel Kamath from the Cleveland Clinic – Young onset colorectal cancer (yoCRC) has been increasing over the past few…
by Hope Rugo, MD – UCSF Dr. Hope S. Rugo is a highly respected oncologist and professor of medicine specializing…
Locally advanced cervical cancer is a significant disease affecting young women, and the standard treatment options have not seen substantial…
The results of the CRUX study, which focused on the safety and feasibility of the JAK stat inhibitor Ruxolitinib in…
Dr. Javier Cortes discussed the PHERGain clinical study is a phase 2 trial focused on the potential deescalation of chemotherapy…
At the (ASCO) 2023 conference, Dr. Manmeet Singh Ahluwalla discussed, researchers presented the final trial report on a phase 1…
Decoding Recurrent Brain Metastases: The Power of 18F-Fluciclovine PET This discusses the challenges in detecting recurrent brain metastases and…